Seminars in Arthritis and Rheumatism
Volume 41, Issue 3 , Pages 346-352 , December 2011

Gonadotropin Releasing Hormone Agonists May Minimize Cyclophosphamide Associated Gonadotoxicity in SLE and Autoimmune Diseases

  • Zeev Blumenfeld, MD

      Affiliations

    • Reproductive Endocrinology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel
    • Corresponding Author InformationAddress reprint requests to Zeev Blumenfeld, MD, Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Rappaport Research Institute, Technion–Faculty of Medicine, Rambam Health Care Campus, Haifa, 31096, Israel
    • ,
  • Or Mischari

      Affiliations

    • Reproductive Endocrinology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel
    • ,
  • Naomi Schultz, RN

      Affiliations

    • The B. Shine Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel
    • ,
  • Nina Boulman, MD

      Affiliations

    • Department of Rheumatology, Bnay-Zion Med Center, Haifa, Israel
    • ,
  • Alexandra Balbir-Gurman, MD

      Affiliations

    • The B. Shine Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel

References 

  1. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum. 1999;42:1785–1796
  2. Madhok R, Wu O. Systemic lupus erythematosus. Am Pham Physician. 2007;76:1351–1353
  3. Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertil Steril. 2009;92:1803–1810
  4. Mackillop LH, Germain SJ, Nelson-Piercy C. Systemic lupus erythematosus. BMJ. 2007;335:933–936
  5. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929–939
  6. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus. 2000;9:401–405
  7. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005;52:2761–2767
  8. Manger K, Wildt L, Kalden JR, Manger B. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev. 2006;5:269–272
  9. Liang LQ, Qiu Q, Yang XY, Xu HS, Ye YJ, Zhan ZP, et al. Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide [in Chinese]. Zhonghua Yi Xue Za Zhi. 2008;88:1009–1011
  10. Mersereau J, Dooley MA. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation. Rheum Dis Clin North Am. 2010;36:99–108
  11. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis (A randomized controlled trial). Kidney Int. 2006;70:732–742
  12. Grootscholten C, Bajema IM, Florquin S, Steenbergen EJ, Peutz-Kootstra CJ, Goldschmeding R, et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum. 2007;56:924–937
  13. Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006;130:182–189
  14. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–3970
  15. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997;40:2187–2198
  16. Jayne D. Review article: Progress of treatment in ANCA-associated vasculitis. Nephrology. 2009;14:42–48
  17. de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: Meta-analysis and critical review. Nephrol Dial Transplant. 2001;16:2018–2027
  18. Sinha R, Dionne JM. Should gonadotropin releasing hormone analogue be administered to prevent premature ovarian failure in young women with systemic lupus erythematosus on cyclophosphamide therapy?. Arch Dis Child. 2008;93:444–445
  19. Blumenfeld Z. Gynaecologic concerns for young women exposed to gonadotoxic chemotherapy. Curr Opin Obstet Gynecol. 2003;15:359–370
  20. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum. 1997;40:1725
  21. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–205
  22. Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease: study of 593 patients. J Rheumatol. 1989;16:328–334
  23. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222–227
  24. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox D. Clinical and immunologic effects of monthly intravenous cyclophosphamide in severe systemic lupus. N Engl J Med. 1988;318:1423–1431
  25. Trevisani VFM, Castro AA, Ferreira Neves Neto JJFNN, Atallah ÁN. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database of Systematic Reviews. 2006;(2):CD002265
  26. Yazici Y. Systemic vasculitis treatment and monitoring update, 2008. Bull NYU Hosp Jt Dis. 2008;66:228–230
  27. Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update. 2008;14:543–552[review]
  28. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91:694–697
  29. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat. 2009;117:561–567
  30. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Giordano M, et al. Role of luteinizing hormone-releasing hormone analog (LH-RHa) triptorelin in preserving ovarian function during chemotherapy for early breast cancer patients: results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. J Clin Oncol. 2010;28(suppl):15s;[abstract 528]
  31. Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, et al. Ovarian preservation by GnRH agonists during chemotherapy: A meta-analysis. J Womens' Health (Larchmt). 2009;18:311–339
  32. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010;122:803–811
  33. Kim SS, Lee JR, Jee BC, Suh CS, Kim SH, Ting A, et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol. 2010;53:740–752
  34. Bedaiwy MA, Abou-Setta AM, Desai N, Hurd W, Starks D, El-Nashar SA, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2011;95:906–914
  35. Beck-Fruchter R, Weiss A, Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: A review of the clinical data. Hum Reprod Update. 2008;14:553–561
  36. Moore HC. Ovarian failure after chemotherapy for breast cancer and the role of gonadotropin-releasing hormone analogs in protection of ovarian function. In: ASCO, Alexandria (VA): American Society of Clinical Oncology Educational Book; 2008;p. 39–42
  37. Meirow D, Rabinovici J, Katz D, Or R, Shufaro Y, Ben-Yehuda D. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer. 2006;107:1634–1641

PII: S0049-0172(11)00150-8

doi: 10.1016/j.semarthrit.2011.05.008

Seminars in Arthritis and Rheumatism
Volume 41, Issue 3 , Pages 346-352 , December 2011

Article Tools